Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Re-treatment in SLE Extension (VOYAGER)
NCT00381810Phase 3Terminated
- Sponsor
- Genentech
- Start
- Jun 2006
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in systemic lupus erythematosus (SLE), sponsored by Genentech. Primary endpoint: Percentage of Participants With at Least 1 Serious Adverse Event at 52 weeks. Started Jun 2006; status: terminated.
02
Drugs
rituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00381810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381810.